Search Results - david+dowling

8 Results

Sort By:

TLR7/8 Ligands for Use in Opioid Vaccines

TLR7/8 Ligands for Use in Opioid Vaccines Ligands with the potential for preventing fatal overdose of opioid users and protect against or treat Opioid Use Disorder patients Technology Overview Building on their work as part of the Precision Vaccines Program, researchers in the Levy lab have developed a method of enhancing immune response to anti-opioid...

Published: 3/24/2026 | Updated: 3/24/2026 | Inventor(s): Ofer Levy, David Dowling, Dheeraj Soni, Sharon Levy, Jay Evans, Marco Pravetoni

Keywords(s): Immunology, Therapeutic, ZZCommon, ZZTherapeutics:Vaccines

Category(s): Technology Classifications > Invention Type, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Disease Area, Technology Classifications > Disease Area > Immunology

The adjuvant combination PVP-AF04 enhances the antibody response towards SARS-CoV antigens

The adjuvant combination PVP-AF04 enhances the antibody response towards SARS-CoV antigens Background As of 2024, SARS-CoV-2 has caused over 1 million deaths in the United States and more than 7 million worldwide. As the virus continues to mutate, it is important to advance immunization efforts to combat the virus’s effects, especially...

Published: 3/24/2026 | Updated: 5/8/2024 | Inventor(s): Ofer Levy, Yoshine Saito, Francesco Borriello, David Dowling, Timothy Yu

Keywords(s):

Category(s): Technology Classifications > Disease Area > Infectious Disease, Technology Classifications > Disease Area > Infectious Disease > COVID-19, Technology Classifications > Invention Type > Vaccines > Adjuvants

SARS-COV-2 Antigen Nanoparticles and Uses Thereof

SARS-COV-2 Antigen Nanoparticles and Uses Thereof Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a novel betacoronavirus, has caused a global health crisis and still poses a substantial risk to public health, leading to over 103 million reported infections in the United States and over 774 million worldwide since 2019. The...

Published: 3/24/2026 | Updated: 2/13/2024 | Inventor(s): Ofer Levy, Francesco Boriello, David Dowling, Sirano Dhe-Pagnon, Hyuk-Su Seo, David Scott, Frederic Feru

Keywords(s):

Category(s): Technology Classifications > Disease Area > Immunology, Technology Classifications > Disease Area > Infectious Disease, Technology Classifications > Disease Area > Infectious Disease > COVID-19, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Invention Type > Vaccines > Adjuvants

MEMPHIS: Modular Evaluation of immunogenicity using Multi-Platform Human In vitro Systems

MEMPHIS: Modular Evaluation of immunogenicity using Multi-Platform Human In vitro Systems Background Though vaccination is one of the greatest accomplishments of modern medicine, there are still challenges to the production of perfectly effective vaccines. These challenges include weakened response by the vaccinated individual’s immune system...

Published: 3/24/2026 | Updated: 5/31/2023 | Inventor(s): Simon van Haren, Ofer Levy, Guzman Sanchez-Schmitz, David Dowling

Keywords(s): Drug Delivery, Immunology, Infectious Disease, Vaccine

Category(s): Technology Classifications > Invention Type, Technology Classifications > Invention Type > Research Tools, Technology Classifications > Invention Type > Research Tools > Assay, Technology Classifications > Invention Type > Vaccines, Technology Classifications > Disease Area, Technology Classifications > Disease Area > Immunology, Technology Classifications > Disease Area > Infectious Disease

Toll-like receptor 2 agonists as vaccine adjuvants

Toll-like receptor 2 agonists as vaccine adjuvants Background Vaccinations play an essential role in preventing infections in the population, reducing the number of deaths in vulnerable individuals, as well as preventing endemics of highly infectious diseases. Because of the protective nature of vaccinations, particularly for those in certain vulnerable...

Published: 3/24/2026 | Updated: 5/31/2023 | Inventor(s): Ofer Levy, David Dowling, Francesco Borriello, Spencer Brightman

Keywords(s): Adjuvants, Infectious Disease, Vaccine

A family of small molecule thiazole amides with in vitro adherence-, NFkB- and IRF-inducing activity towards human leukocytes and vaccine adjuvant in mice in vivo.

A Family of Small Molecule Thiazole Amides with in vitro Adherence Inducing Activity Towards Human Leukocytes and Vaccine Adjuvant in Mice in vivo The small molecule family has multiple activities towards human leukocytes in vitro and adjuvant activity in vivo Background Since the immune system plays an essential role in major diseases such...

Published: 3/18/2026 | Updated: 3/7/2023 | Inventor(s): Ofer Levy, David Dowling, Francesco Borriello

Keywords(s):

TLR7/8 Adjuvant Overcomes Newborn Hyporesponsiveness to Pneumococcal Conjugate Vaccine

TLR7/8 Adjuvant Overcomes Newborn Hyporesponsiveness to Pneumococcal Conjugate Vaccine The molecule 3M-052 offers effective immunization with one birth dose, representing a new paradigm in early life vaccine development Technology Overview Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical...

Published: 3/24/2026 | Updated: 3/6/2023 | Inventor(s): Ofer Levy, David Dowling, Jay Evans, Helene Brazin-Lee, David Burkhart, Alyson Smith

Keywords(s): Immunology, Therapeutic, ZZCommon, ZZTherapeutics:Vaccines

STING Agonists as Immunomodulators and Vaccine Adjuvants

STING Agonists as Immunomodulators and Vaccine Adjuvants STING agonists proven to be effective vaccine adjuvants and immunomodulators in newborns Background Infectious diseases are the leading cause of morbidity and mortality in early life and immunization is a key preventive strategy. Vaccine adjuvants can enhance, prolong, and modulate immune responses...

Published: 3/30/2026 | Updated: 3/6/2023 | Inventor(s): Ofer Levy, Carlo Pietrasanta, David Dowling, Francesco Borriello

Keywords(s): Immunology, Therapeutic, ZZCommon, ZZTherapeutics:Vaccines